Syndax Pharmaceuticals (SNDX) Non-Current Debt (2020 - 2024)

Syndax Pharmaceuticals' Non-Current Debt history runs 4 years deep, the most recent figure standing at $331.6 million for Q4 2024.

• In Q4 2024, Non-Current Debt changed N/A year-over-year to $331.6 million; the TTM figure through Dec 2024 stood at $331.6 million (changed N/A YoY), while the FY2024 annual figure was $331.6 million, changed N/A from the prior year.
• Non-Current Debt was $331.6 million for Q4 2024 at Syndax Pharmaceuticals, up from $13.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $331.6 million in Q4 2024 to a low of $11.0 million in Q3 2021.
• Historically, Non-Current Debt has averaged $45.3 million across 4 years, with a median of $17.8 million in 2020.
• Biggest YoY gain for Non-Current Debt was 11.56% in 2021; the steepest drop was 45.07% in 2021.
• A 4-year view of Non-Current Debt shows it stood at $17.8 million in 2020, then rose by 11.56% to $19.9 million in 2021, then slumped by 34.69% to $13.0 million in 2022, then jumped by 2451.68% to $331.6 million in 2024.
• The last three Non-Current Debt figures came in at $331.6 million (Q4 2024), $13.0 million (Q2 2022), and $16.5 million (Q1 2022), per Business Quant data.